|
MYUNGMOON PHARM is a South Korean pharmaceutical company operating in two main segments: pharmaceuticals/biotechnology and services. In the pharmaceutical segment, the company develops and manufactures generic drugs and improved new drugs, including MMP-320 for hyperlipidemia and MMP-305. It also holds license-in agreements for products such as Tego Capsule 20/25 and Buprain Patch. The company conducts research and development through its corporate research institute and development division, focusing on formulations and drug development. In the services segment, the company operates a 9-hole public golf course in Icheon, Gyeonggi Province, which it acquired in 2009. The company sells its pharmaceutical products through cash and credit sales, with payment terms ranging from one to six months. Its business activities are subject to strict regulatory frameworks, including the Pharmacist Act and Good Manufacturing Practice (GMP) standards. The company maintains production facilities in Hwaseong, Gyeonggi Province, and manages its operations through a dedicated organizational structure for research, development, and manufacturing. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage mmpharm.co.kr |
| Sector Healthcare | IR page mmpharm.co.kr/m/index.asp | |
|
Tags
generic drugs, improved new drugs, hyperlipidemia, pharmaceutical manufacturing, golf course operations, license-in agreements, drug development, formulation research, MMP-320, MMP-305, MMP-125, Tego Capsule 20/25, Buprain Patch, Myungmoon Bio
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| P/E | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 1.9% |
| ROI | 1.9% |
| ROIC | 3.7% |
| Profit margin | 0.97% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | No |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 58.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.247B | 186.443B | 169.567B | 152.135B | 137.76B | 127.853B | 149.346B | 147.499B | 140.138B | 142.18B | 125.101B | 105.421B | 103.723B |
| Net profit | 1.895B | -3.035B | -5.394B | 9.265B | -7.086B | -27.753B | -20.833B | 327.851M | 8.131B | 6.746B | -16.135B | 761.49M | 1.026B |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.